Drugs in ATC Class J05

Up to Top Level ATC Classes

Up to J - Antiinfectives for systemic use

Subclasses in ATC: J05 - ANTIVIRALS FOR SYSTEMIC USE

J05A - DIRECT ACTING ANTIVIRALS

Market Dynamics and Patent Landscape for ATC Class J05 - Antivirals for Systemic Use

Last updated: July 27, 2025

Introduction

The ATC classification J05 encompasses antivirals for systemic use, representing a critical segment within the global pharmaceutical market. This class includes medications designed to treat a spectrum of viral infections, including HIV/AIDS, hepatitis B and C, influenza, herpes, and emerging viral threats such as COVID-19. The ongoing evolution of viral diseases, combined with technological advances and patent strategies, continually shapes the market dynamics and intellectual property (IP) landscape for these therapeutics.

Market Overview

Global Market Size and Growth Trajectory

The global antivirals market for systemic use has experienced robust growth, driven by increasing viral infections, expanding indications, and technological advancements. As reported by Market Research Future, the market was valued at approximately USD 43 billion in 2021 and is projected to reach USD 70 billion by 2028, growing at a CAGR of around 7.1% during 2022-2028[1]. Factors fueling this growth include the rising prevalence of HIV/AIDS, hepatitis, and viral respiratory infections, coupled with the development of novel antivirals.

Key Market Segments

• HIV/AIDS Therapies: The largest segment, with drugs like tenofovir, emtricitabine, and integrase inhibitors. The advent of long-acting injectables and fixed-dose combinations enhances adherence and market appeal.
• Hepatitis B and C Treatments: The introduction of direct-acting antivirals (DAAs) such as sofosbuvir and glecaprevir has revolutionized hepatitis C treatment, leading to high cure rates.
• Influenza Antivirals: Oseltamivir and zanamivir dominate, but newer agents such as baloxavir offer alternatives.
• Herpes and Varicella: Acyclovir remains standard; however, newer drugs addressing resistant strains are under development.

Emerging Trends

• Pandemic Influence: The COVID-19 pandemic positioned antiviral research at the forefront, with repurposing existing drugs like remdesivir gaining prominence. The experience catalyzed investments in broad-spectrum antivirals.
• Personalized Medicine: Genetic markers guide therapy choices, especially for HIV and hepatitis, influencing market segmentation and drug development strategies.
• Biologics and Novel Modalities: mRNA-based antivirals and monoclonal antibodies are under investigation, promising future market diversification.

Patent Landscape Overview

Patent Filing Trends

The patent landscape for J05 antivirals reflects intense innovation, especially in the fields of HIV and hepatitis C. Notably:

• Patent filings surged from the early 2000s, correlating with the advent of protease inhibitors and nucleotide analogs.
• Between 2010 and 2020, filings for direct-acting antivirals (DAAs) increased exponentially, with many patents granted for combination therapies and formulation innovations[2].

Key Patent Holders and Strategic Players

• Gilead Sciences: Dominates the hepatitis C space, holding extensive patents on sofosbuvir and its combinations.
• ViiV Healthcare (GSK, Pfizer, Shionogi): Landmark patents for HIV drugs, including integrase inhibitors like dolutegravir.
• GlaxoSmithKline, Merck, AbbVie: Significant patent portfolios covering various antiviral classes, formulations, and delivery methods.
• Emerging Innovators: Companies like BioCryst and Moderna are patenting novel antiviral mechanisms, especially targeting resistant strains and emerging viruses.

Patent Challenges and Patent Cliff

• Patent expirations, notably of blockbuster drugs such as Truvada (Gilead), have led to generic competition, exerting downward pressure on prices.
• Patent litigation and patent evergreening strategies continue to influence the competitive landscape.

Regulatory and Patent Policy Impacts

• Patent life extensions through supplementary protection certificates (SPCs) are common.
• Governments and international organizations advocate for balancing patent rights with affordability, impacting patent strategies.

Market Dynamics Influences

R&D and Innovation

Continuous innovation remains vital. The focus includes:

• Developing next-generation drugs with improved efficacy and safety.
• Addressing resistance mechanisms that undermine existing therapeutics.
• Expanding indications to prevent and treat emerging viral infections.

Pricing and Reimbursement

High drug development costs and patent expiries influence pricing. Payers seek cost-effective therapies, encouraging biosimilar and generic entries post-patent expiry.

Regulatory Environment

Streamlined approval pathways, such as FDA’s Fast Track and EMA’s PRIME, accelerate access to novel antivirals, incentivizing innovation and patent activity.

Competitive Landscape

Major pharmaceutical corporations dominate, but biotech firms and academia contribute significantly to IP development. Strategic licensing and collaborations are common to access advanced technologies and expand patent portfolios.

Future Outlook

Advancements in genomics, AI-driven drug discovery, and biologics are poised to redefine the patent landscape. The emergence of broad-spectrum antivirals targeting multiple viruses or host mechanisms could disrupt current market hierarchies. Additionally, pandemic preparedness investments will likely sustain innovation and IP filings across viral therapeutics.

Key Takeaways

• The J05 antivirals market is characterized by substantial growth, driven by rising viral disease prevalence, novel therapeutic modalities, and pandemic influences.
• Patent strategies are central to competitive positioning, with dominant players holding extensive portfolios, though expiries open opportunities for generics.
• Innovation focus includes addressing resistance, improving safety profiles, and expanding indications.
• Regulatory incentives facilitate rapid development and market entry, shaping IP strategies.
• Emerging technologies and biologics will influence future market dynamics, with patent landscapes shifting toward broader spectrum and personalized antiviral therapies.

FAQs

1. How does patent expiry affect the antiviral market?
Patent expiries allow generic manufacturers to enter the market, increasing competition, reducing drug prices, and expanding access. However, they also challenge originator companies to innovate or develop new patents to maintain market dominance.

2. What are the main patent challenges faced by antiviral developers?
Patent challenges include patent litigations, patent term extensions, and potential patent thickets. Developing broad-spectrum or resistant-strain therapies often involves complex patent strategies to protect novel mechanisms.

3. How has COVID-19 impacted patent activity in the J05 class?
The pandemic spurred increased patent filings related to repurposed drugs and novel antiviral candidates targeting coronaviruses, expanding the patent landscape and emphasizing rapid innovation.

4. Are biologics becoming significant within the J05 antiviral class?
Yes, biologics such as monoclonal antibodies and mRNA vaccines are increasingly studied for viral infections, potentially leading to significant patent landscapes distinct from small-molecule drugs.

5. What role do regulatory policies play in shaping the patent landscape?
Regulatory incentives, fast-track approvals, and patent extensions influence patent strategies by encouraging innovation, expediting market access, and incentivizing IP protection for new therapeutics.

---

Sources:

[1] Market Research Future, "Antiviral Drugs Market Overview," 2022.
[2] Global Data, "Patent Analysis of Antiviral Drugs," 2021.